Theraclone Sciences, Inc. Announces Positive Top-line Data from a Phase 1 Trial of its Therapeutic Antibody Directed at Influenza A

Published: May 15, 2012

SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections. TCN-032 was well tolerated throughout the study, with no dose-limiting toxicities or serious adverse events observed, and demonstrated a favorable immunogenicity profile.

Back to news